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Neointimal hyperplasia on a cell-seeded
polytetrafluoroethylene graft is promoted by
transfer of tissue plasminogen activator gene and
inhibited by transfer of nitric oxide synthase gene
Hong Yu, PhD,a,b Wangde Dai, MD, PhD,d Zhe Yang, MD, PhD,b Rita L. Romaguera, MD,c Paul
Kirkman,d and Vincent L. Rowe, MD,d Miami, Fla, and Los Angeles, Calif
Objective:The objective of this study was to examine the effect of tissue plasminogen activator (tPA) and endothelial nitric
oxide synthase (eNOS) on thrombosis and neointimal hyperplasia on a polytetrafluoroethylene (PTFE) graft seeded with
smooth muscle cells (SMCs).
Methods: SMCs retrovirally transduced with tPA and eNOS genes were seeded on PTFE grafts and then implanted into the
infrarenal rabbit aorta. Thrombosis and neointimal hyperplasia on the grafts were examined after 30 and 100 days of
implantation.
Results: At 30 days of implantation, thrombus was observed on the luminal surface of both unseeded and SMC seeded
control grafts, whereas grafts seeded with SMCs secreting tPA were nearly free of thrombus. At 100 days, the neointima
on grafts seeded with tPA transduced SMCs was significantly thicker (925 150 m, n 5) than neointima on the other
grafts (range, 132 to 374 m; P< .001). Neointima thickness on grafts seeded with eNOS transduced SMCs (154 27
m) was similar to that of unseeded grafts (132  16 m, P > .05); both were thinner than those on grafts seeded with
SMCs transduced with only lacZ gene (287 35 m). The ratio of seeded cells in the neointima was significantly higher
on SMC/tPA grafts (46% 8%) than SMC/NOS grafts (21% 6%, P< .05), indicating tPA transduced cells proliferated
more than eNOS transduced cells.
Conclusions: Engineered tPA expression in seeded SMCs causes significantly more neointimal hyperplasia, despite the
favorable inhibition of luminal thrombus. eNOS expression in the seeded cells inhibits neointimal hyperplasia. ( J Vasc
Surg 2005;41:122-9.)
Clinical relevance: Vascular prosthetic grafts are vulnerable to thrombosis and restenosis resulting in high incidence of
limb loss when autogenous vein is not available. Modification of vascular prosthetic grafts to more closely mimic natural
conditions may protect against clot formation and may have an immediate and prolonged effect on vascular surgical
results. This study examined the patency of a prosthetic vascular graft by seeding the grafts with genetically engineered
cells to prevent thrombosis and restenosis.Most vascular interventions fail as a result of thrombo-
sis and restenosis. Small diameter vascular prosthetic grafts
are particularly vulnerable. Seeding a polytetrafluoroethyl-
ene (PTFE) graft luminal surface with endothelial cells
(ECs) has been advocated as a means to reduce surface
thrombogenicity and improve patency.1,2 However, the
outcomes of EC seeding were not consistent in humans.3-6
The major problem encountered is that ECs adhere poorly
to prosthetic graft materials and are easily stripped away
when exposed to blood flow.
Smooth muscle cells (SMCs) secrete larger amounts of
extracellular matrix (ECM) that enable cells to adhere more
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122firmly to the graft than ECs. We have shown that SMCs
seeded beneath ECs on PTFE grafts improved EC reten-
tion both in vitro and in vivo.7,8 In addition to enhance-
ment of cell retention, seeded SMCs can serve as a candi-
date for delivery of a therapeutic protein because the
multilayer formation of SMCs allows more “exogenous
gene product forming” units per unit volume than ECs,
which grow as a monolayer. Seeding of SMCs on grafts has
been studied by a few groups as a potential vehicle for gene
replacement therapy.9-12
Engineered overexpression of tissue plasminogen acti-
vator (tPA) in seeded cells was proposed as a means to
enhance fibrinolytic capability and therefore inhibit throm-
bosis and restenosis after vascular interventions. tPA is a
thrombolytic protease that converts inactive plasminogen
into active plasmin, which then degrades fibrin complexes,
a major component of thrombus. tPA expression has been
engineered into ECs and SMCs by viral transfer of the tPA
gene.12-14 Adenoviral-mediated tPA gene transfer has been
reported to prevent arterial thrombus formation.15 The
direct benefit of tPA secretion would be to alter the kinetics
of fibrin cross-linking, diminishing local thrombosis. An
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result from destabilization of the platelet coagulum on the
luminal surface.
It is not clear whether seeding SMCs on PTFE will
result in uncontrolled SMC proliferation leading to neoin-
timal hyperplasia. Even with restoration of normal EC
coverage, SMC hyperplasia takes longer to return to a
homeostatic state.16,17 Increased concentration of nitric
oxide has been shown to inhibit SMC proliferation and
mitogenesis responsible for intimal hyperplasia.18,19 Gene
transfer of NOS has also been successful in reducing intimal
hyperplasia.20-24 NOS catalyzes the production of nitric
oxide (NO), a potent vasodilator that inhibits platelet
aggregation and adhesion25 as well as SMC proliferation
and migration.16,25,26
Herein we report that grafts seeded with SMCs over-
expressing tPA resulted in a thicker neointima than that in
controls after implantation in a rabbit aorta, despite the
favorable inhibition of laminated thrombus. Transduced
eNOS in seeded cells diminished the neointimal hyperpla-
sia.
MATERIALS AND METHODS
Isolation of SMCs. The New Zealand White rabbits
were treated in accordance with the Guide for the Care and
Use of Laboratory Animals (National Institutes of Health),
and the experimental protocol was approved by the Uni-
versity of Southern California Animal Care and Use Com-
mittee. The isolation and culture of SMCs from the jugular
veins of New Zealand White rabbits were described previ-
ously.8 SMCs were characterized by cellular morphology
under phase contrast microscopy, as well as by the presence
of cytoplasmic smooth muscle -actin. SMCs were used at
passage 2-3 for gene transfer and at passage 3-5 for cell
seeding.
Retroviral vectors and cell transduction. The repli-
cation-incompetent murine leukemia virus (MuLV) de-
rived viral vectors, pseudotyped with the vesicular stomati-
tis virus G envelope glycoprotein (VSV-G), were used to
mediate the gene transfer into SMCs. Vector plasmids
pG1nBgSvNa, pG1wTSvNa,7 and pLCNSN21 carry genes
encoding for nuclear-localized -galactosidase (-gal),
wild-type human tPA, and human endothelium-specific
constitutive nitric oxide synthase (eNOS), respectively. Vi-
ral vector supernatants were generated from 293/GPG-
based producer cell lines as described previously.7 The viral
titers were between 106 to 107 colony-forming units (cfu)
per milliliter analyzed by neomycin resistance assay. Trans-
duction of SMCs with viral vectors was achieved27 by
overlaying viral supernatants containing 8 g/mL poly-
brene on cells plated on culture dishes for 2 hours, followed
by G418 (Gibco BRL, Gaithersburg, Md) selection.
All seeded cells were transduced with a retroviral vector
carrying the -gal reporter gene lacZ. This was necessary to
distinguish these seeded cells from endogenous cells depos-
ited onto PTFE grafts after implantation. The transduced
cells were identified as the blue cells after x-gal staining.12In addition to lacZ gene transduction, three groups of
SMCs were further transduced with the vectors carrying
genes coding for tPA, tPA and eNOS, or eNOS genes to
generate SMC/tPA, SMC/tPANOS, and SMC/NOS,
respectively. To transduce multi-genes into the same SMC,
two or more vectors carrying the specified genes were
mixed and overlayed on cells. Incubating cells with the two
vectors effected double transduction. The co-transduction
efficiency was reduced by approximately 10% from single
transduction of 90% to double transduction of 80%, which
was determined by using two marker vectors (G1nBgSvNa
for -gal and LGFPSN for green fluorescence protein).
Cell seeding and graft implantation. Expanded
PTFE grafts (thin wall, internal diameter 4 mm), provided
by IMPRA, Inc (Tempe, Ariz), were coated with fibronec-
tin (0.1 mg/ml in phosphate-buffered saline; Gibco BRL)
and seeded as described previously7 with specified cells.
Briefly, fibronectin coated grafts were filled with cell sus-
pension (3  105 cells/mL), heat-crimped at both ends,
and rotated at 1 rpm for 2 hours at 37°C. After the cell
suspension was removed, the grafts were cultured in a
culture dish with medium for 1 day before being implanted
into animals. The cell coverage is approximately 500 cells/
mm2 with more than 80% confluent on the graft surface.
Autologous cells were harvested from each rabbit and
implanted back to the same rabbit after they were trans-
duced and seeded on PTFE grafts. Five types of PTFE
grafts were prepared. Type I grafts were not seeded with
cells. Type II grafts were seeded with SMCs transduced
with lacZ gene only. Type III grafts were seeded with
SMC/tPA, type IV with SMC/tPANOS, and type V
with SMC/NOS. Three rabbits were used in each group
except that there were 10, 5, and 4 rabbits in types I, III,
and V, respectively, at 100-day implantation. There were
two groups within type I graft at 100 days, fibronectin
coated or non-coated graft, with each group having five
animals. No significant difference was found between these
two groups. We combined them into n  10. Operational
failed (including paralyzed) animals that were killed at day 1
were excluded from data analysis.
Grafts (5-cm long) were implanted into the infrarenal
aorta in end-to-side fashion as described previously.8 At the
time of graft harvest after 30- or 100-day implantation,
heparin (400 IU/rabbit) was injected intravenously to
prevent fresh clot formation. The graft segments were
removed, and the animals were killed with an overdose of
sodium pentobarbitol (125 mg/kg).
tPA assays. The enzyme activity and antigen concen-
tration of tPA in the medium that was conditioned with
transduced cells were measured by using assay kits from
Biopool (Ventura, Calif). Briefly, the transduced cells and
the recovered grafts (1-cm long) were cultured inDulbecco
modified Eagle medium (Gibco) containing 0.1% fetal
bovine serum for 24 hours. The conditioned medium was
collected and centrifuged. The concentrations of tPA in the
conditioned media were determined by measuring the tPA
antigen concentration with TintElize tPA enzyme-linked
immunosorbent assay kit (Biopool, Ventura, Calif). The
f graft
.001
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mogenic assay with Chromolize tPA assay kit (Biopool).
The results were expressed as ng (Ag) or IU (activity) per
105 cells or per cm graft in 24 hours.
Neointimal measurement. The recovered grafts after
30- or 100-day implantation were treated as described
previously8 tomeasure thrombus formation and neointimal
thickness. One part of the graft was opened longitudinally
for luminal analysis for thrombosis. The second part (two
thirds of graft) was assigned into 3 areas: (1) proximal
anastomosis (“A”), (2) proximal one-third of graft (“P”),
and (3) mid-graft (“M”). Grafts in each area were further
cut into two segments; one segment was embedded in
optimum cutting temperature compound for frozen sec-
tion, and the other segment was fixed with 10% formalde-
hyde and paraffin embedded. Frozen sections (4-m thick)
were stained with X-gal and counterstained with eosin to
visualize the seeded cells (blue) and endogenous cells (red),
which were counted separately under a microscope. Two to
three sections per segment were analyzed. The area of
neointima was measured under the microscope by an indi-
vidual blinded to sample source with a standard micro-ruler
as a reference. The cell density, expressed in cells per mm2,
was determined by dividing the cell number per section by
the area of neointima in that section.
The thickness of the neointima on a graft was measured
with a microscopic ruler at eight evenly distributed loca-
tions on the graft circumference. The average of the eight
values was used to represent the neointimal thickness in
that graft segment. A final neointimal thickness of a graft
was yielded from the average of the data on positions A, P,
and M (Table).
Histology analysis. Paraffin embedded samples were
cut into 4-m thick sections and stained as described
previously21 with hematoxylin-eosin, Masson trichrome
(DAKO, Carpinteria, Calif) for collagen, phosphotungstic
acid (Sigma, St Louis, Mo) and hematoxylin (PTAH) for
Neointima thickness (m) on the recovered PTFE grafts*
Graft type
(seeded cells)
30 Days
A P M Avera
I (No cell) 48  49 191  220 134  138 124  7
II (SMC/lacZ) 109  14 71  33 101  62 94  2
III (SMC/tPA) 252  140 351  81 399  68 334  7
IV (SMC/
tPANOS)
222  212 263  243 317  153 267  4
V (SMC/NOS) 44  22 158  144 199  86 133  8
*Circumference of each PTFE section wasmeasured at eight evenly distribute
anastomosis; P, proximal one-third of graft; M, mid-graft) per rabbit. Avera
average  standard deviation in m from numbers of rabbits in parenthese
†P values were from comparison between 30 days and 100 days of the corre
by one-way ANOVA at 30 days are I vs II  .05; I vs III 	 .05; I vs IV  .0
vs V 	 .05; IV vs V  .05. P values for comparison among different types o
II vs III 	 .001; II vs IV  .05; II vs V  .05; III vs IV 	 .001; III vs V 	fibrin, Verhoeff’s elastic stain (American MasterTech Sci-entific, Lodi, Calif) for elastin. The paraffin sections were
also immunohistochemically stained for tPA, eNOS,
smooth muscle –actin (SMA), muscle specific actin
(MSA), and anti-proliferating cell nuclear antigen (PCNA).
Anti-
human tPA mouse monoclonal immunoglobulin G1 (1:
100 dilution) was purchased from Oncogene Research
Products (Boston, Mass). Biotinylated anti-human eNOS
goat immunoglobulin G (1:5 dilution) was from R & D
Systems, Inc (Minneapolis, Minn). Monoclonal mouse an-
tibodies of anti-human SMA (clone 1A4, 1:250 dilution),
anti-human MSA (clone HHF35, 1:200), and anti-human
PCNA (clone PC10, 1:100) were purchased from DAKO.
A standard avidin-biotin peroxidase technique was used
after antigen retrieval by steamer in citric buffer (DAKO).
Statistical analysis. Experimental values were ob-
tained from at least three repeats and expressed as mean 
standard deviation. One-way analysis of variance (ANOVA)
with GraphPad (San Diego, Calif) prism program was used
to compare data from multiple groups in the Table and Fig
1. Other statistical comparisons were performed by using
2-tailed Student t test. Significance was attributed to a P
value of less than .05.
RESULTS
Gene expression. After retroviral tPA gene transfer,
production of tPA from SMCs increased from being unde-
tectable in SMCs to detectable at 10.2  5.4 ng/105
cells/24 h (n  10). tPA activity increased accordingly to
0.57 0.09 IU/105 cells/24 h. The tPA concentration in
the conditioned medium incubated with the recovered
grafts seeded with SMC/tPA (type III) or SMC/
tPANOS (type IV) was similar (1.0  0.4 ng/cm
graft/24 h). Their tPA activity was 0.11  0.08 IU/cm
graft/24 h. There was no detectable tPA activity from the
recovered types I, II, and V grafts. No significant difference
of tPA production between 30-day and 100-day implanta-
lantation period
100 Days
P
value†A P M Average
126  129 150  129 121  108 132  16 (10) .05
318  180 293  159 249  127 287  35 (3) 	.05
817  328 1096  141 861  383 925  150 (5) 	.001
404  191 445  192 272  79 374  90 (3) .05
182  156 128  54 153  37 154  27 (4) .05
ts, which were then averaged to give the thickness per position (A, proximal
the mean of three different positions. The values in this table represent the
ing groups (t test). P values for comparison among different types of grafts
V  .05; II vs III 	 .01; II vs IV 	 .05; II vs V  .05; III vs IV  .05; III
s at 100 days are I vs II 	 .05; I vs III 	 .001; I vs IV 	 .05; I vs V  .05;
; IV vs V 	 .05.Imp
ge
2 (3)
0 (3)
5 (3)
8 (3)
0 (3)
d poin
ge is
s.
spond
5; I vstion was observed, which indicates retroviral transduced
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rabbit.
Immunostaining of the recovered grafts with antibod-
ies against human tPA and eNOS showed tPA and eNOS
positive cells in the neointima of type III and IV grafts,
respectively (Fig 2, a and c). Neither tPA nor eNOS was
detected in the neointima of type II graft that was seeded
with SMCs transduced with only lacZ gene. These data
confirmed the long-term expression of the transduced
genes.
Thrombus formation. No grafts were occluded at 30
Fig. 1. Cell content in neointima. a, Density of seeded cells, which
was calculated from lacZ positive cells in a measured area of
neointima. b, Density of total cells, which was calculated from total
cells counted in a measured area of neointima. P  .05 for all
comparisons in (a) and (b) between different grafts (ANOVA). c,
Total neointimal cells. Total cells in one section were calculated
from the density of total cells multiplied by the area of neointima.
The data are from 100-day explants. *P	 .05 compared with type
I graft. P  .05 for all other comparisons (ANOVA).days. Thrombus covered 40% 13% of the luminal surfaceof type I grafts (n 3) and 26% 4% of the luminal surface
of type II grafts (n 3) at 1 month after implantation (Fig
3, top panel). There was minimal thrombus seen on types
III, IV, and V grafts (	5%) 30 days after implantation. The
native arteries proximal and distal to the graft segment were
Fig. 2. Immunostaining of neointima. Paraffin sections of grafts
seeded with SMC/tPA (a), SMC/tPANOS (c), or SMC (b, d)
were stained with antibody against human tPA (a, b) or antibody
against human eNOS (c, d). Black arrows indicate positively
stained cells in brown.White arrows indicate negtively stained cells
with nuclear stained in blue.
Fig. 3. Effect of tPA on thrombosis and neointima formation on
PTFE graft. PTFE grafts (4 mm inside diameter) were seeded with
no cell (I), SMC/lacZ (II), SMC/tPA (III), SMC/tPANOS
(IV), or SMC/NOS (V) and then implanted into rabbit aorta as
bypass grafts for 30 and 100 days. The recovered grafts were
opened longitudinally (30 days, top panel). Thrombus (red) was
observed on the luminal surface of type I and type II grafts. The
grafts explanted at 100 days were patent except the graft seeded
with SMC/tPA (middle panel). The sections of the grafts were
stained with X-gal and hematoxylin-eosin to show the seeded cells
(blue) and endogenous cells (pink) (bottom panels). Arrow 1,
neointima; arrow 2, PTFE.free of thrombus in all rabbits.
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100 days. Their lumen was filled with neointima except for
a thin plug of thrombus in the center of the lumen (Fig 3,
III, middle panel). No other type of grafts was occluded.
Neointima formation. Neointimal thickness at three
positions of the grafts, the proximal anastomosis, the prox-
imal one third of the graft, and the middle of graft, was not
significantly different (P .1) for all grafts implanted for 30
or 100 days (Table). The neointima on all type of grafts was
thicker at 100 days compared to the same group 30 days
after implantation. Neointimal thickness was not signifi-
cantly different between type I and type II grafts 30 days
after implantation (P  .05, Table) but was so at 100 days
(P 	 .05). This indicates that SMCs seeded alone could
incite more neointimal hyperplasia in the long-term.
On the other hand, the neointima in type III grafts was
already significantly thicker than the other non-tPA types of
grafts at 30 days of implantation (P 	 .05 for type III vs
types I, II, and V) (Table). The neointimal thickness of type
III grafts at 100 days of implantation was 925  150 m,
which was significantly thicker than all other type of grafts.
These data indicate that tPA expression in the seeded cells
could stimulate neointimal hyperplasia.
Among the SMC seeded grafts, SMC/NOS grafts had
the thinnest neointima (154  27 m), similar to that of
grafts without cell seeding (Table). Comparing the effect of
transduction of lacZ versus NOS gene and tPA versus tPA
 NOS gene, adding the eNOS gene to SMCs resulted in
a thinner neointima at 100-day implantation (II vs V and
III vs IV, P  .01), although they were not significantly
different at 30-day implantation (P  .27). These data
indicate that eNOS expression in the seeded cells inhibits
neointimal hyperplasia.
Neointimal cell density. The number of neointimal
cells on each section of slides of 100-day explants was
counted. There was no significant difference on either the
density of seeded cells (Fig 1, a) or the density of total cells
(Fig 1, b) in the neointima of all grafts recovered 100 days
after implantation. However, the absolute cell number on
neointima of type III grafts (6746  2854 cells/section;
Fig. 4. Cell migration through the PTFE wall. PTFE grafts
seeded with SMC/lacZ were implanted into rabbit aorta for 30
days. After recovery, the grafts were sectioned and stained with
x-gal and hematoxylin-eosin. a, Cells in adventitial surface (A)
(red) infiltrated into luminal surface (L) of PTFE graft with porous
structure (in brown). b, Seeded cells (blue) migrated from luminal
surface to adventitial surface.Fig 1, c) was higher than that of other grafts. These dataindicate that cells on type III grafts proliferate more and
produce more ECM than cells on other types of grafts.
Origin of neointimal cells. The origin of cells in
neointima could come from four sources: seeded cells, cells
deposited from the circulation, cells migrating from the
adjacent artery, and cells migrating from adventitial side of
grafts. Because all seeded cells were transduced with the
reporter lacZ gene, the seeded cells and their progeny can
be differentiated from the endogenous cells populated on
the neointima by the X-gal staining. Nearly half the cells
(46%  8%) in the neointima of the grafts seeded with
SMC/tPA were lacZ positive. This significantly (P 	 .05)
exceeded the percentage of seeded cells on type II (38% 
8%), type IV (22%  7%), and type V grafts (21%  5%).
Because not 100% seeded cells had the lacZ gene due to
lower co-transduction efficiency, and furthermore, lacZ
gene expression could be inactivated in vivo, the number of
seeded cells in the neointima could be underestimated.
Higher percentage of seeded cells in SMC/tPA graft indi-
cates more proliferation of tPA transduced cells. Lower
percentage of seeded cells in types IV and V grafts indicates
less proliferation of eNOS transduced cells. No cells were
stained blue in control type I unseeded grafts.
Infiltration and migration of cells through the porous
PTFE wall were observed (Fig 4). Cells on the periadven-
titial side infiltrated to the luminal side through the pores
on the graft wall after 30-day implantation (Fig 4, a). This
infiltration could also contribute to the intimal hyperplasia
on the luminal surface. Similarly, seeded cells were ob-
served to migrate from luminal surface of the graft to the
periadventitial side of the graft through the pores on the
graft wall (Fig 4, b).
Neointima content analysis. To identify the cellular
and matrix property of neointima, recovered grafts at 100
days of implantation were analyzed with histologic stains.
Cells within the neointima were long and spindle shaped
(Fig 5, a and e). They were positively stained with antibody
against SMA (Fig 5, b and f) and MSA (data not shown).
Collagen-rich matrix in the neointima was illustrated by
Masson trichrome stain (Fig 5, c and g). The fibrin stain by
PTAH was negative in the neointima layer. Verhoeff-van
Gieson stain for elastin fibers was negative in the neointima
on all PTFE grafts (data not shown). The results indicate
that the major composition of the neointima is SMC and
ECM. There aremore PCNA positive cells in the neointima
of type III grafts (Fig 5, h) than other types of grafts (Fig 5,
d), indicating that cells in the neointima of type III grafts
proliferated faster than cells on the other types of grafts.
Thrombus was observed at the center of the occluded type
III grafts on hematoxylin-eosin stained sections. The
PTAH stain and factor VIII immunostaining showed a
fibrin-poor but platelet-rich thrombus (data not shown).
DISCUSSION
Seeding tPA-transduced cells onto grafts has been pro-
posed as a means to enhance the thrombolytic activity of
the graft, thereby increasing graft patency.12-14 Indeed, we
observed a thrombus-free lumen on grafts seeded with
proli
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panel). In comparison, there was thrombus on other con-
trol grafts that did not hypersecrete tPA (Fig 3, I and II top
panel). This result agrees with the report that adenoviral-
mediated tPA gene transfer prevents arterial thrombus for-
mation.15
However, tPA expression from seeded SMCs stimu-
lated intimal hyperplasia. Neointima on the grafts seeded
with SMC hypersecreting tPA (type III and IV grafts) was
significantly thicker than those not expressing tPA (Table).
The neointima on the type III grafts was more than seven-
fold and three-fold thicker than those on the type I and II
grafts, respectively. The stenosis in type III grafts was so
severe at 100 days that tPA expression could not inhibit
thrombosis of the small remaining lumen, and the grafts
were eventually occluded by thrombus in the middle of the
grafts. This hypothesis was supported by histology analysis,
which showed that thrombus in type III grafts was Factor
VIII positive and PTAH negative. These data demon-
strated that the thrombus is formed by platelets with little
fibrin.
The impact of the tPA gene transfer on intimal hyper-
plasia is controversial in the literature. It was reported that
intimal hyperplasia in an allograft heart transplantation was
reduced 64% by ex vivo transfer of human tPA gene into a
rabbit heart.28 However, tPA gene transfer in the injured
artery has been reported to cause a thicker neointima
compared to controls.29 Re-endothelialization with endo-
thelial progenitor cells that had been transduced with tPA
gene aggravated intimal hyperplasia.30
A possible mechanism of tPA effect on neointimal
hyperplasia is that tPA activates plasminogen into plasmin,
which is a nonspecific serine protease and can activate
matrix metalloproteinases, a family of proteolytic en-
zymes.31 Both plasmin and matrix metalloproteinases de-
grade many components of the ECM. ECM degradation
can cause vascular remodeling by inducing cell proliferation
Fig. 5. Analysis of neointima. Paraffin sections of grafts
were stained with hematoxylin-eosin (a, e), antibody fo
antibody for PCNA (d, h). Nuclear are purple in hematox
is blue and cells are pink in trichome staining; nuclear ofand migration,32 as well as ECM deposition,33 which arenecessary steps leading to neointimal development.34-36
The breakdown of ECM releases the embedded growth
factors that stimulate cell proliferation.37 We have demon-
strated in vitro that overexpression of tPA in SMCs resulted
in ECM degradation and promoted SMC proliferation and
migration (manuscript in preparation).
There were more total cells on the type III grafts
compared with other types of grafts (Fig 1, c). The ratio of
seeded cells in the neointima was higher on SMC/tPA
grafts (46%) than other cell-seeded grafts (21% to 38%).
More PCNA positive cells were also observed on SMC/
tPA grafts (Fig 5, h). These data indicate that cells on
SMC/tPA grafts proliferate more than cells on other types
of grafts.
Because the neointima is thicker and the total neointi-
mal area is commensurately greater on the SMC/tPA
grafts, this results in a cell density that is not significantly
different from other grafts. The higher absolute number of
cells but similar cell density indicates that accompanying
the cellular proliferation, there must be more ECM pro-
duced, resulting in a thicker neointima but similar cell
density. This eventuates in more rapid narrowing of the
vessel and subsequent occlusion.
On the other hand, the tPA gene transduced into rabbit
SMC is from human cDNA. Although there is a possibility
that expression of human tPA in this rabbit model induced
an immunoreaction that incites graft occlusion, both type
III and type IV grafts secreted human tPA, but occlusion
occurred only in type III grafts. This result makes immu-
noreaction less likely.
Neointimal thickness on the unseeded grafts pro-
gressed little from 30 days to 100 days, although their
surface had more thrombus than grafts secreting tPA at 30
days (Table). However, the neointima of grafts seeded with
SMCs progressed significantly between 30 and 100 days.
This indicates that seeding a PTFE graft with SMCs results
in a thicker neointima. SMCs were selected as the seeding
ed with SMC (upper panel) or SMC/tPA (lower panel)
oth muscle –actin (b, f), Masson trichome (c, g), and
osin staining; SMCs are brown in SMA staining; collagen
ferating cells are dark blue in PCNA staining.seed
r smo
ylin-ecells in lieu of ECs because SMCs adhere better on the
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of delivering an engineered gene product.
Modulation of the SMC proliferation can be achieved
by dual seeding an EC layer overlying SMC. ECs have been
reported to inhibit SMC growth in a co-culture of ECs and
SMCs.38,39 In vivo studies have shown that extensive neo-
intimal proliferation after luminal injury was restricted by
re-endothelialization of vessel walls.40 Our prior investiga-
tion found that the neointimal thickness for dual cell–
seeded grafts (ECs on top of SMCs) was significantly
thinner than those seeded with SMC/lacZ and was similar
with that from grafts without cell seeding after 100-day
implantation.8
Another way to modulate neointimal hyperplasia from
SMC seeding is to modify SMCs in vitro by transducing
them with genes that modulate SMC proliferation, such as
NOS20 or homeobox transcription factor Gax.41 Higher
NOS expression increases the production of NO. We,
along with others, have reported that transfer of eNOS
gene can reduce neointima formation.20-24 In this study,
we found that the neointima on type V grafts was the
thinnest among the cell-seeded grafts and was similar to
that of unseeded grafts. This indicates that eNOS can
modulate the growth of seeded SMCs on the grafts (Ta-
ble). The neointima of type IV grafts is significantly thinner
than that of type III grafts, indicating that effect of eNOS
on inhibition of SMC proliferation could overcome some
of the effect of tPA on stimulation of SMC proliferation.
NO also exerts antithrombotic effects in arterial endothe-
lium. Early studies demonstrated that NO inhibits platelet
activation and platelet recruitment to the growing throm-
bus.42 The antithrombotic effects of NO on arterial endo-
thelium are also attributable to inhibition of the expression
of the prothrombotic protein plasminogen activator inhib-
itor-1.43,44 The antithrombotic effect of NO explains our
observation that minimal thrombus formed on type V
grafts at 30 days.
A new strategy toward surface engineering of a throm-
boresistant graft without inducing excessive neointimal
hyperplasia could be to replace the wild-type tPA with a
zymogen tPA.7,45 A zymogen tPA has a reduced protease
activity after it is synthesized inside a cell. It is not activated
until it binds to extracellular fibrin. This lower protease
activity will result in less ECM degradation and less neoin-
timal hyperplasia when tPA is used to develop a thrombo-
resistant graft.
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